Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Jantscher, Florian ^a   Pirker, Christine ^a   Mayer, Christoph Erik ^a,b   Berger, Walter ^a   Sutterluety, Hedwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; CYCLIN D1; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOBLASTOMA PROTEIN; AURKA PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MUTANT PROTEIN; PROTEIN SERINE THREONINE KINASE; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANEUPLOIDY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOSIS INHIBITION; PROTEIN PHOSPHORYLATION; CELL CULTURE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; METABOLISM; MITOSIS; TIME;

CELL PROLIFERATION; CELLS, CULTURED; CYCLIN D1; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION; HUMANS; MITOSIS; MUTANT PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RAS GTPASE-ACTIVATING PROTEINS; S PHASE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79952585985     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-28     Document Type: Article

References (45)

1. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001, 11:49-54. 10.1016/S0962-8924(00)01880-8, 11166196.
2. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003, 15:672-83. 10.1016/j.ceb.2003.10.013, 14644191.
3. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV. Aurora A, meiosis and mitosis. Biol Cell 2004, 96:215-29. 10.1016/j.biolcel.2003.09.008, 15182704.
4. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998, 20:189-93. 10.1038/2496, 9771714.
5. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114:585-98. 10.1016/S0092-8674(03)00642-1, 13678582.
6. Dutertre S, Cazales M, Quaranta M, Froment C, Trabut V, Dozier C, et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci 2004, 117:2523-31. 10.1242/jcs.01108, 15128871.
7. Dutertre S, Prigent C. Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint. Mol Interv 2003, 3:127-30. 10.1124/mi.3.3.127, 14993419.
8. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. Embo J 2002, 21:483-92. 10.1093/emboj/21.4.483, 125866, 11847097.
9. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001, 92:370-3. 10.1002/ijc.1200, 11291073.
10. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J 1998, 17:3052-65. 10.1093/emboj/17.11.3052, 1170645, 9606188.
11. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003, 9:991-7.
12. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002, 94:1320-9.
13. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001, 84:824-31. 10.1054/bjoc.2000.1684, 2363814, 11259099.
14. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004, 4:927-36. 10.1038/nrc1502, 15573114.
15. Zhang D, Hirota T, Marumoto T, Shimizu M, Kunitoku N, Sasayama T, et al. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 2004, 23:8720-30. 10.1038/sj.onc.1208153, 15480417.
16. Fukuda T, Mishina Y, Walker MP, DiAugustine RP. Conditional transgenic system for mouse aurora a kinase: degradation by the ubiquitin proteasome pathway controls the level of the transgenic protein. Mol Cell Biol 2005, 25:5270-81. 10.1128/MCB.25.12.5270-5281.2005, 1140609, 15923640.
17. Li CC, Chu HY, Yang CW, Chou CK, Tsai TF. Aurora-A overexpression in mouse liver causes p53-dependent premitotic arrest during liver regeneration. Mol Cancer Res 2009, 7:678-88. 10.1158/1541-7786.MCR-08-0483, 19435814.
18. Lu LY, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X, et al. Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem 2008, 283:31785-90. 10.1074/jbc.M805880200, 2581543, 18801727.
19. Pirker C, Lotsch D, Spiegl-Kreinecker S, Jantscher F, Sutterluty H, Micksche M, et al. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Exp Dermatol 19:1040-7. 10.1111/j.1600-0625.2010.01182.x, 21087322.
20. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004, 279:52175-82. 10.1074/jbc.M406802200, 15469940.
21. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004, 36:55-62. 10.1038/ng1279, 14702041.
22. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-8. 10.1038/sj.onc.1207396, 14743206.
23. Rong R, Jiang LY, Sheikh MS, Huang Y. Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene 2007, 26:7700-8. 10.1038/sj.onc.1210575, 17563743.
24. Gigoux V, L'Hoste S, Raynaud F, Camonis J, Garbay C. Identification of Aurora kinases as RasGAP Src homology 3 domain-binding proteins. J Biol Chem 2002, 277:23742-6. 10.1074/jbc.C200121200, 11976319.
25. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004, 18:2699-711. 10.1101/gad.1256504, 15545627.
26. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997, 8:287-301. 276080, 9190208.
27. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007, 129:1351-63. 10.1016/j.cell.2007.04.035, 2504417, 17604723.
28. Mori D, Yamada M, Mimori-Kiyosue Y, Shirai Y, Suzuki A, Ohno S, et al. An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation by modulation of microtubule dynamics. Nat Cell Biol 2009, 11:1057-68. 10.1038/ncb1919, 19668197.
29. Lee CY, Andersen RO, Cabernard C, Manning L, Tran KD, Lanskey MJ, et al. Drosophila Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation. Genes Dev 2006, 20:3464-74. 10.1101/gad.1489406, 1698452, 17182871.
30. Wang H, Somers GW, Bashirullah A, Heberlein U, Yu F, Chia W. Aurora-A acts as a tumor suppressor and regulates self-renewal of Drosophila neuroblasts. Genes Dev 2006, 20:3453-63. 10.1101/gad.1487506, 1698451, 17182870.
31. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10:825-41. 10.1038/nrc2964, 21102634.
32. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003, 278:51786-95. 10.1074/jbc.M306275200, 14523000.
33. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007, 27:4513-25. 10.1128/MCB.02364-06, 1900054, 17438137.
34. Reed CA, Mayhew CN, McClendon AK, Knudsen ES. Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. J Biol Chem 2010, 285:1089-96. 10.1074/jbc.M109.043380, 2801236, 19887370.
35. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29:313-26. 10.1089/jir.2008.0027, 2755091,2755091, 19441883.
36. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004, 91:69-136. full_text, 15327889.
37. Lademann UA, Romer MU. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost 2008, 100:1041-6.
38. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001, 54:145-8. 10.1136/mp.54.3.145, 1187052, 11376125.
39. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602. 10.1016/S0092-8674(00)81902-9, 9054499.
40. Pirker C, Lötsch D, Spiegl-Kreinecker S, Jantscher F, Sutterlüty H, Micksche M, et al. Response of experimental malginant melanoma models to the pan-Aurora kinase inhibitor VE-465. Experimental Dermatology 2010, 19(12):1040-7. 10.1111/j.1600-0625.2010.01182.x, 21087322.
41. Mayer CE, Haigl B, Jantscher F, Siegwart G, Grusch M, Berger W, et al. Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cell Mol Life Sci 2010, 67:3299-311. 10.1007/s00018-010-0379-6, 20461437.
42. Sutterluty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, et al. Down-Regulation of Sprouty2 in Non-Small Cell Lung Cancer Contributes to Tumor Malignancy via Extracellular Signal-Regulated Kinase Pathway-Dependent and -Independent Mechanisms. Mol Cancer Res 2007, 5:509-20. 10.1158/1541-7786.MCR-06-0273, 17510316.
43. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999, 1:207-14. 10.1038/12027, 10559918.
44. Haigl B, Mayer CE, Siegwart G, Sutterluty H. Sprouty4 levels are increased under hypoxic conditions by enhanced mRNA stability and transcription. Biol Chem 2010, 391:813-21. 10.1515/BC.2010.082, 20482313.
45. Sutterluety H, Bartl S, Doetzlhofer A, Khier H, Wintersberger E, Seiser C. Growth-regulated antisense transcription of the mouse thymidine kinase gene. Nucleic Acids Res 1998, 26:4989-95. 10.1093/nar/26.21.4989, 147947, 9776764.